抗胸腺細胞球蛋白在移植物抗宿主病預防方案中的有效性和安全性Meta分析_《中國循證醫學雜志》

作者：

劉云 , 袁進 , 麻亮亮 ,  賈永前

四川大學華西醫院血液內科（成都?610041）;

關鍵詞：

抗胸腺細胞球蛋白移植物抗宿主病生存率死亡率 Meta分析系統評價

DOI：

10.7507/1672-2531.20110117

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　采用Cochrane系統評價方法評價異基因造血干細胞移植移植物抗宿主病（graft-versus-host disease，GVHD）預防方案中加用抗胸腺細胞球蛋白（antithymocyte globulins，ATGs）的有效性和安全性。
方法　計算機檢索PubMed （1966～2011.3）、EMbase （1974～2011.3）、The Science Citation Index databases （1900～2011.3）、Cochrane 圖書館（1996～2011.3）、CBM （1978～2011.3）和CNKI（1979～2011.3），并手工檢索其他相關文獻，查找相關隨機及非隨機對照試驗。由兩位研究者按照納入與排除標準篩選文獻、提取資料和評價納入研究的方法學質量后，采用RevMan5.0.2軟件進行Meta分析。
結果　共納入13個研究，包括2個隨機對照試驗（310例患者），11個非隨機對照研究（1480例患者）。Meta分析結果顯示：與未加用ATG組相比，GVHD預防過程中加用ATG組患者在急性GVHD Ⅱ-Ⅳ發生率，急性GVHD III-IV發生Ⅲ-Ⅳ率、慢性GVHD（局限性+廣泛性）發生率、慢性GVHD（廣泛性）發生率、總體生存率、非復發死亡率及復發率的RR值及其95%CI分別為0.77 （0.67，0.87）、0.54 （0.44，0.68）、0.58 （0.51，0.65）、0.35 （0.26，0.46）、1.14 （1.04，1.25）、0.81 （0.69，0.93）和 1.24 （0.98，1.57）。
結論　本Meta分析結果顯示，在異基因造血干細胞移植GVHD預防方案中加用ATG可以降低急性、慢性GVHD發生率，降低非復發死亡率，提高總體生存率，而對移植后復發率無明顯影響。

引用本文： 劉云,袁進,麻亮亮,賈永前. 抗胸腺細胞球蛋白在移植物抗宿主病預防方案中的有效性和安全性Meta分析. 中國循證醫學雜志, 2011, 11(6): 661-669. doi: 10.7507/1672-2531.20110117 復制

1.	1 Lee SJ, Klein JP, Barrett AJ, et al . Severity o f chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood , 2002, 100(2): 406-14.
2.	2 Bolwell B, Sobecks R, Pohlman B, et al . A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant , 2004, 34(7): 621-625.
3.	3 Ram R, Gafter-Gvili A, Yeshurun M, et al . Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant , 2009, 43(8): 643-653.
4.	4 Pavletic SZ, Carter SL, Kernan NA, et al . Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood , 2005, 106(9): 3308-3313.
5.	5 Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood , 2001, 98(12): 3192-3204.
6.	6 Storb R, Gluckman E, Thomas ED, et al . Treatment of established human graft-versus-host disease by antithymocyte globulin. Blood , 1974, 44(1): 56-75.、.
7.	9 Michallet M, Le QH, Mohty M, et al . Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Exp Hematol , 2008, 36(5): 535-544.
8.	10 Wagner JE, Thompson JS, Carter SL, et al . Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomized phase II-III trial. Lancet , 2005, 366(9487): 733-741.
9.	11 Lu DP, Dong L, Wu T, et al . Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/ haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood , 2006, 107(8): 3065-3073.
10.	12 Tanosaki R, Uike N, Utsunomiya A, et al . Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant , 2008, 14(6): 702-708.
11.	13 Finke J, Schmoor C, Lang H , et al . Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol , 2003, 21(3): 506-513.
12.	14 Bacigalupo A, Lamparelli T, Bruzzi P, et al . Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood , 2001, 98(10): 2942-2947.
13.	15 Finke J, Bethge WA, Schmoor C, et al . Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol , 2009, 10(9): 855-864.
14.	16 Bacigalupo A, Lamparelli T, Gualandi F, et al . Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. Biol Blood Marrow Transplant , 2002, 8(12): 656-661.
15.	17 Ayuk F, Perez-Simon JA, Shimoni A, et al . Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica , 2008, 93(9): 1343-1350.
16.	18 Schetelig J, Bornhäuser M, Kiehl M, et al . Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation-a retrospective analysis. Bone Marrow Transplant , 2004, 33(5): 483-490.
17.	19 Russell JA, Turner AR, Larratt L, et al . Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant , 2007, 13(3): 299-306.
18.	20 Mohty M, Labopin M, Balère ML, et al . Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire. Leukemia , 2010, 24(11): 1867-1874.
19.	21 Remberger M, Storer B, Ringdén O, et al . Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant , 2002, 29(5): 391-397.
20.	22 Basara N, Baurmann H, Kolbe K, et al . Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant , 2005, 35(10): 1011-1018.
21.	23 Zander AR, Kröger N, Schleuning M, et al . ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant , 2003, 32(4): 355-361.
22.	24 Bonifazi F, Bandini G, Stanzani M, et al . In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. Bone Marrow Transplant , 2005, 35(10): 1025-1026.
23.	28 Beiras-Fernandez A, Thein E, Hammer C. Induction of immunosuppression with polyclonal anti-thymocyte globulins: an overview. Exp Clin Transplant , 2003, 1(2): 79-84.
24.	29 Genestier L, Fournel S, Flacher M, et al . Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood , 1998, 91(7): 2360-2368.
25.	30 Michallet MC, Preville X, Flacher M, et al . Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation , 2003, 75(5): 657-662.
26.	31 Zand MS, Vo T, Huggins J, et al . Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation , 2005, 79(11): 1507-1515.
27.	32 Fang L, Fehse B, Engel M, et al . Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. Transplantation , 2005, 79(3): 369-371.
28.	33 Préville X, Nicolas L, Flacher M, et al . A quantitative flow cytometry assay for the preclinical testing and pharmacological monitoring of rabbit antilymphocyte globulins (rATG). J Immunol Methods , 2000, 245(1-2): 45-54.
29.	35 Weisdorf DJ, Anasetti C, Antin JH, et al . Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood , 2002, 99(6): 1971-1977.
30.	36 Marks DI, Cullis JO, Ward KN, et al . Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years. Ann Intern Med , 1993, 119(3): 207-214.
31.	37 Schmitz N, Beksac M, Hasenclever D, et al . Transplantation of mobilized peripheral blood cells to HLA identical siblings with standard risk leukaemia. Blood , 2002, 100(3): 761-767.
32.	38 Cutler C, Giri S, Jeyapalan S, et al . Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol , 2001, 19(16): 3685-3691.
33.	39 Duggan P, Booth K, Chaudhry A, et al . Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant , 2002, 30(10): 681-686.
34.	40 Remberger M, Mattsson J, Hausenberger D, et al . Genomic tissue typing and optimal antithymocyte globuline dose using unrelated donors results in similar survival and relapse as HLA-identical siblings in haematopoietic stem-cell transplantation for leukaemia. Eur J Haematol , 2008, 80(5): 419-428.
35.	41 Kröger N, Zabelina T, Binder T, et al . HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen. Biol Blood Marrow Transplant , 2009, 15(4): 454-462.
36.	Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2009. Available from: URL: http://www.cochrane-handbook.org/.
37.	劉建平. 非隨機研究的系統評價方法（一）. 中國循證醫學, 2001, 1(4): 239-243.
38.	吳秉毅, 郭坤元, 宋朝陽, 等. 預處理方案中加抗胸腺細胞球蛋白減少異基因造血干細胞移植慢性移植物抗宿主病. 中華血液學雜志, 2004, 25(2): 91-94.
39.	劉代紅, 劉婧, 劉開彥, 等. 含與不含抗胸腺細胞球蛋白的兩種預處理方案早期毒性的比較. 中華血液學雜志, 2009, 30(8): 519-523.
40.	張曉輝, 黃曉軍, 劉開彥, 等. 抗胸腺細胞球蛋白在HLA配型部分相合的造血干細胞移植患者的藥代動力學. 中國實驗血液學雜志, 2007, 15(1): 152-155.
41.	黃曉軍. 移植物抗宿主病的預防與抗胸腺細胞球蛋白. 中華血液學雜志, 2010, 31(8): 568-571.

1. 1 Lee SJ, Klein JP, Barrett AJ, et al . Severity o f chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood , 2002, 100(2): 406-14.
2. 2 Bolwell B, Sobecks R, Pohlman B, et al . A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant , 2004, 34(7): 621-625.
3. 3 Ram R, Gafter-Gvili A, Yeshurun M, et al . Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant , 2009, 43(8): 643-653.
4. 4 Pavletic SZ, Carter SL, Kernan NA, et al . Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood , 2005, 106(9): 3308-3313.
5. 5 Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood , 2001, 98(12): 3192-3204.
6. 6 Storb R, Gluckman E, Thomas ED, et al . Treatment of established human graft-versus-host disease by antithymocyte globulin. Blood , 1974, 44(1): 56-75.、.
7. 9 Michallet M, Le QH, Mohty M, et al . Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Exp Hematol , 2008, 36(5): 535-544.
8. 10 Wagner JE, Thompson JS, Carter SL, et al . Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomized phase II-III trial. Lancet , 2005, 366(9487): 733-741.
9. 11 Lu DP, Dong L, Wu T, et al . Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/ haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood , 2006, 107(8): 3065-3073.
10. 12 Tanosaki R, Uike N, Utsunomiya A, et al . Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant , 2008, 14(6): 702-708.
11. 13 Finke J, Schmoor C, Lang H , et al . Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol , 2003, 21(3): 506-513.
12. 14 Bacigalupo A, Lamparelli T, Bruzzi P, et al . Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood , 2001, 98(10): 2942-2947.
13. 15 Finke J, Bethge WA, Schmoor C, et al . Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol , 2009, 10(9): 855-864.
14. 16 Bacigalupo A, Lamparelli T, Gualandi F, et al . Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. Biol Blood Marrow Transplant , 2002, 8(12): 656-661.
15. 17 Ayuk F, Perez-Simon JA, Shimoni A, et al . Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica , 2008, 93(9): 1343-1350.
16. 18 Schetelig J, Bornhäuser M, Kiehl M, et al . Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation-a retrospective analysis. Bone Marrow Transplant , 2004, 33(5): 483-490.
17. 19 Russell JA, Turner AR, Larratt L, et al . Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant , 2007, 13(3): 299-306.
18. 20 Mohty M, Labopin M, Balère ML, et al . Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire. Leukemia , 2010, 24(11): 1867-1874.
19. 21 Remberger M, Storer B, Ringdén O, et al . Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant , 2002, 29(5): 391-397.
20. 22 Basara N, Baurmann H, Kolbe K, et al . Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant , 2005, 35(10): 1011-1018.
21. 23 Zander AR, Kröger N, Schleuning M, et al . ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant , 2003, 32(4): 355-361.
22. 24 Bonifazi F, Bandini G, Stanzani M, et al . In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. Bone Marrow Transplant , 2005, 35(10): 1025-1026.
23. 28 Beiras-Fernandez A, Thein E, Hammer C. Induction of immunosuppression with polyclonal anti-thymocyte globulins: an overview. Exp Clin Transplant , 2003, 1(2): 79-84.
24. 29 Genestier L, Fournel S, Flacher M, et al . Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood , 1998, 91(7): 2360-2368.
25. 30 Michallet MC, Preville X, Flacher M, et al . Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation , 2003, 75(5): 657-662.
26. 31 Zand MS, Vo T, Huggins J, et al . Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation , 2005, 79(11): 1507-1515.
27. 32 Fang L, Fehse B, Engel M, et al . Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. Transplantation , 2005, 79(3): 369-371.
28. 33 Préville X, Nicolas L, Flacher M, et al . A quantitative flow cytometry assay for the preclinical testing and pharmacological monitoring of rabbit antilymphocyte globulins (rATG). J Immunol Methods , 2000, 245(1-2): 45-54.
29. 35 Weisdorf DJ, Anasetti C, Antin JH, et al . Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood , 2002, 99(6): 1971-1977.
30. 36 Marks DI, Cullis JO, Ward KN, et al . Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years. Ann Intern Med , 1993, 119(3): 207-214.
31. 37 Schmitz N, Beksac M, Hasenclever D, et al . Transplantation of mobilized peripheral blood cells to HLA identical siblings with standard risk leukaemia. Blood , 2002, 100(3): 761-767.
32. 38 Cutler C, Giri S, Jeyapalan S, et al . Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol , 2001, 19(16): 3685-3691.
33. 39 Duggan P, Booth K, Chaudhry A, et al . Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant , 2002, 30(10): 681-686.
34. 40 Remberger M, Mattsson J, Hausenberger D, et al . Genomic tissue typing and optimal antithymocyte globuline dose using unrelated donors results in similar survival and relapse as HLA-identical siblings in haematopoietic stem-cell transplantation for leukaemia. Eur J Haematol , 2008, 80(5): 419-428.
35. 41 Kröger N, Zabelina T, Binder T, et al . HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen. Biol Blood Marrow Transplant , 2009, 15(4): 454-462.
36. Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2009. Available from: URL: http://www.cochrane-handbook.org/.
37. 劉建平. 非隨機研究的系統評價方法（一）. 中國循證醫學, 2001, 1(4): 239-243.
38. 吳秉毅, 郭坤元, 宋朝陽, 等. 預處理方案中加抗胸腺細胞球蛋白減少異基因造血干細胞移植慢性移植物抗宿主病. 中華血液學雜志, 2004, 25(2): 91-94.
39. 劉代紅, 劉婧, 劉開彥, 等. 含與不含抗胸腺細胞球蛋白的兩種預處理方案早期毒性的比較. 中華血液學雜志, 2009, 30(8): 519-523.
40. 張曉輝, 黃曉軍, 劉開彥, 等. 抗胸腺細胞球蛋白在HLA配型部分相合的造血干細胞移植患者的藥代動力學. 中國實驗血液學雜志, 2007, 15(1): 152-155.
41. 黃曉軍. 移植物抗宿主病的預防與抗胸腺細胞球蛋白. 中華血液學雜志, 2010, 31(8): 568-571.

《中國循證醫學雜志》

抗胸腺細胞球蛋白在移植物抗宿主病預防方案中的有效性和安全性Meta分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《中國循證醫學雜志》

抗胸腺細胞球蛋白在移植物抗宿主病預防方案中的有效性和安全性Meta分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料